Tatsis Ourania
SEC CIK 1789815 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | EVP, Chief Reg, Quality Off | 53.6K | — | $19.14M | 55 | 2022-02-01 | 2026-07-21 |
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 55
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-23 16:15 | 2026-07-21 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +8,251 | 53.6K | +18% | $0 | |
| T | 2026-07-07 16:15 | 2026-07-02 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $524.99 | -1,500 | 45.3K | -3% | -$787.5K |
| 2026-02-26 | 2026-02-25 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $486.35 | -260 | 46.8K | -0.6% | -$126.5K | |
| 2026-02-26 | 2026-02-24 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $485.11 | -1,627 | 47.0K | -3% | -$789.3K | |
| M | 2026-02-19 | 2026-02-17+ | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $483.52 | -977 | 49.0K | -2% | -$472.4K |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $483.75 | -2,294 | 49.6K | -4% | -$1.11M | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +5,789 | 51.9K | +13% | $0 | |
| 2026-02-18 | 2026-02-13 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $487.76 | -3,804 | 47.6K | -7% | -$1.86M | |
| 2026-02-18 | 2026-02-13 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $499.99 | -1,500 | 46.1K | -3% | -$750.0K | |
| 2026-02-12 | 2026-02-10 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $468.41 | -2,140 | 51.9K | -4% | -$1.00M | |
| 2026-02-12 | 2026-02-11 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $460.43 | -466 | 51.4K | -0.9% | -$214.6K | |
| M | 2026-01-26 | 2026-01-22 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +11.7K | 50.2K | +31% | $0 |
| 2026-01-09 | 2026-01-07 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $474.99 | -4,500 | 42.3K | -10% | -$2.14M | |
| 2025-12-05 | 2025-12-03 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $449.99 | -4,500 | 46.8K | -9% | -$2.02M | |
| 2025-03-12 | 2025-03-10 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $499.99 | -3,242 | 51.2K | -6% | -$1.62M | |
| 2025-03-06 | 2025-03-04 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $485.49 | -4,058 | 54.5K | -7% | -$1.97M | |
| 2025-02-28 | 2025-02-26 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $479.61 | -4,962 | 59.1K | -8% | -$2.38M | |
| 2025-02-28 | 2025-02-27 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $475.34 | -530 | 58.5K | -0.9% | -$251.9K | |
| 2025-02-26 | 2025-02-24 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $483.28 | -3,310 | 64.4K | -5% | -$1.60M | |
| 2025-02-26 | 2025-02-25 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $480.95 | -354 | 64.0K | -0.5% | -$170.3K | |
| 2025-02-19 | 2025-02-14 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $463.46 | -2,293 | 67.9K | -3% | -$1.06M | |
| 2025-02-19 | 2025-02-18 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $455.06 | -244 | 67.7K | -0.4% | -$111.0K | |
| 2025-02-14 | 2025-02-12 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +6,211 | 70.2K | +10% | $0 | |
| 2025-02-12 | 2025-02-10 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $467.98 | -2,143 | 64.3K | -3% | -$1.00M | |
| 2025-02-12 | 2025-02-11 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $459.83 | -310 | 64.0K | -0.5% | -$142.5K | |
| M | 2025-02-06 | 2025-02-04 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +17.4K | 59.4K | +41% | $0 |
| 2024-06-05 | 2024-06-03 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $460.00 | -2,175 | 49.1K | -4% | -$1.00M | |
| M | 2024-06-03 | 2024-05-30+ | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $441.99 | -4,600 | 51.3K | -8% | -$2.03M |
| 2024-02-27 | 2024-02-23 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $431.79 | -3,309 | 56.2K | -6% | -$1.43M | |
| 2024-02-27 | 2024-02-26 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $425.70 | -354 | 55.8K | -0.6% | -$150.7K | |
| 2024-02-23 | 2024-02-21 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $421.77 | -360 | 59.5K | -0.6% | -$151.8K | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $422.54 | -7,872 | 60.3K | -12% | -$3.33M |
| 2024-02-21 | 2024-02-20 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $420.79 | -480 | 59.8K | -0.8% | -$202.0K | |
| 2024-02-13 | 2024-02-12 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $420.24 | -314 | 68.2K | -0.5% | -$132.0K | |
| 2024-02-13 | 2024-02-09 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $422.74 | -2,100 | 68.5K | -3% | -$887.8K | |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +22.0K | 70.6K | +45% | $0 |
| 2023-08-25 | 2023-08-23 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $355.00 | -2,500 | 48.6K | -5% | -$887.5K | |
| 2023-08-14 | 2023-08-10 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $345.79 | -5,750 | 51.1K | -10% | -$1.99M | |
| M | 2023-02-28 | 2023-02-27 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $287.48 | -354 | 56.8K | -0.6% | -$101.8K |
| 2023-02-28 | 2023-02-24 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $289.12 | -3,308 | 57.2K | -5% | -$956.4K | |
| M | 2023-02-22 | 2023-02-21 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $293.75 | -480 | 60.8K | -0.8% | -$141.0K |
| 2023-02-22 | 2023-02-17 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $292.85 | -4,498 | 60.9K | -7% | -$1.32M | |
| M | 2023-02-16 | 2023-02-14 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $298.52 | -320 | 65.7K | -0.5% | -$95.5K |
| M | 2023-02-14 | 2023-02-13 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $298.99 | -275 | 66.0K | -0.4% | -$82.2K |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $297.02 | -4,372 | 69.0K | -6% | -$1.30M |
| M | 2023-02-03 | 2023-02-01 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +24.3K | 52.3K | +87% | $0 |
| M | 2022-08-10 | 2022-08-09 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $298.97 | -1,400 | 47.2K | -3% | -$418.6K |
| M | 2022-03-21 | 2022-03-17 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $250.11 | -2,833 | 47.4K | -6% | -$708.6K |
| M | 2022-02-28 | 2022-02-25 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $230.95 | -325 | 50.3K | -0.6% | -$75.1K |
| 2022-02-28 | 2022-02-24 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $227.86 | -2,590 | 50.5K | -5% | -$590.2K | |
| M | 2022-02-22 | 2022-02-18 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $231.00 | -519 | 53.3K | -1.0% | -$119.9K |
| 2022-02-22 | 2022-02-17 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $232.51 | -4,114 | 53.6K | -7% | -$956.5K | |
| 2022-02-14 | 2022-02-10 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $237.74 | -1,230 | 58.0K | -2% | -$292.4K | |
| M | 2022-02-14 | 2022-02-11 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $235.09 | -290 | 57.7K | -0.5% | -$68.2K |
| M | 2022-02-03 | 2022-02-01 | VRTX | Vertex Pharmaceuticals | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +27.7K | 59.3K | +88% | $0 |
Purchase Sale Sale after option exercise All abbreviations